

Mats Brune

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2293776/publications.pdf>

Version: 2024-02-01

40
papers

1,793
citations

394286

19
h-index

330025

37
g-index

41
all docs

41
docs citations

41
times ranked

2069
citing authors

#	ARTICLE	IF	CITATIONS
1	Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. <i>Blood Advances</i> , 2022, 6, 2723-2730.	2.5	19
2	Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2022, 107, 1479-1482.	1.7	15
3	Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation. <i>Vaccine</i> , 2021, 39, 1035-1038.	1.7	5
4	Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 796072.	2.2	2
5	Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 109-111.	1.4	13
6	Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, e49-e53.	1.2	4
7	Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies. <i>Vaccine</i> , 2020, 38, 1084-1088.	1.7	5
8	Minimal residual disease assessed with deep sequencing of <i>NPM1</i> mutations predicts relapse after allogeneic stem cell transplant in AML. <i>Leukemia and Lymphoma</i> , 2019, 60, 409-417.	0.6	15
9	Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. <i>Blood</i> , 2019, 134, 1558-1561.	0.6	38
10	High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia: A Nationwide Swedish Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1970-1974.	2.0	11
11	Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1770-1778.	2.0	25
12	Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. <i>Bone Marrow Transplantation</i> , 2019, 54, 1764-1774.	1.3	33
13	The HLA-B *21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. <i>Blood</i> , 2019, 133, 1479-1488.	0.6	50
14	Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1318-1318.	0.6	0
15	Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia - A Swedish nationwide cohort study. <i>European Journal of Haematology</i> , 2018, 100, 613-620.	1.1	13
16	A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1243-1249.	2.0	49
17	Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia. <i>Cancer Immunology Research</i> , 2018, 6, 1110-1119.	1.6	8
18	A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 1122-1129.	1.3	19

#	ARTICLE	IF	CITATIONS
19	Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316). <i>Blood</i> , 2018, 132, 205-205.	0.6	2
20	NOX2-dependent immunosuppression in chronic myelomonocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2017, 102, 459-466.	1.5	21
21	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1473-1484.	2.0	45
22	Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. <i>Haematologica</i> , 2017, 102, 1683-1690.	1.7	65
23	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 5, e1041701.	2.1	34
24	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. <i>Blood</i> , 2016, 128, 4561-4561.	0.6	10
25	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 7586-7596.	0.8	13
26	Incidence and Outcome in Aplastic Anemia Diagnosed 2000-2011 - a Nationwide Swedish Registry Study. <i>Blood</i> , 2016, 128, 3905-3905.	0.6	0
27	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. <i>Oncotarget</i> , 2015, 6, 42569-42574.	0.8	35
28	Genital Chronic Graft-versus-Host Disease in Females: A Cross-Sectional Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 806-811.	2.0	32
29	Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2014, 32, 8592-8592.	0.8	0
30	Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. <i>Blood</i> , 2012, 119, 5832-5837.	0.6	75
31	Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. <i>Haematologica</i> , 2012, 97, 1904-1908.	1.7	44
32	Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. <i>European Journal of Haematology</i> , 2009, 83, 99-107.	1.1	35
33	Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥ 50 Years. <i>Blood</i> , 2007, 110, 1095-1095.	0.6	0
34	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. <i>Blood</i> , 2006, 108, 88-96.	0.6	226
35	Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. <i>American Journal of Clinical Nutrition</i> , 1999, 70, 240-246.	2.2	240
36	Histamine Protects T Cells and Natural Killer Cells Against Oxidative Stress. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 1135-1144.	0.5	81

#	ARTICLE	IF	CITATIONS
37	Haemoglobin K ^A Δ In as <i>de novo</i> mutations in Sweden: Diagnosis by PCR and specific enzymatic cleavage. European Journal of Haematology, 1994, 52, 156-161.	1.1	3
38	Inhibition of haem-iron absorption in man by calcium. British Journal of Nutrition, 1993, 69, 533-540.	1.2	141
39	Bioavailability in Man of Iron in Human Milk and Cow's Milk in Relation to Their Calcium Contents. Pediatric Research, 1992, 31, 524-527.	1.1	93
40	Iron Absorption from Bread in Humans: Inhibiting Effects of Cereal Fiber, Phytate and Inositol Phosphates with Different Numbers of Phosphate Groups. Journal of Nutrition, 1992, 122, 442-449.	1.3	273